JAZZ Venture Bets on the Human

A child playing a video game would not ordinarily attract the attention of a venture capitalist interested in medicine. The child might attract a parent asking for the tablet back. But in June 2020, Akili’s EndeavorRx received FDA authorization to improve attention in certain children with ADHD. A familiar household argument had acquired an unfamiliar possibility: sometimes the game was the treatment.

JAZZ Venture Partners was an investor in Akili. That choice helps explain a firm whose portfolio can otherwise resemble a collision between several different conferences. There are medical technologies, consumer health products and enterprise software businesses. The connecting question is what technology can help a person do better. The interesting complication is how to turn that improvement into a business.

01 / The person is the starting point

JAZZ calls its ambition “Unlocking Human Potential.” Read generously, that covers an enormous territory. Read carefully, it supplies a useful filter: start with a human limitation, then ask which scientific or technical advance could change it. An industry label becomes less important than the problem being solved.

Consider two investments. Oura makes a ring and companion software that help people understand sleep and recovery. Cadence Neuroscience is developing an implanted stimulation system for drug-resistant epilepsy. One belongs in a consumer shopping decision; the other must travel through clinical research and regulatory review. The common investor does not make their evidence requirements interchangeable.

Oura’s own account of its $100 million Series C in 2021 names JAZZ among the investors. Cadence’s 2023 financing announcement identifies JAZZ as its Series A lead and a participant in the subsequent $26 million Series B. These are investments in separate companies pursuing different routes to human benefit.

02 / Put the surgeon beside the operator

Andrew Firlik, a managing partner, previously practiced neurosurgery. John Spinale brings consumer technology and digital media experience. Co-founder Adam Gazzaley also co-founded Akili and built a career studying cognition. That combination suggests why the firm can take a medical video game seriously: the proposition demands questions about both the brain and the experience on the screen.

The firm’s offering is capital plus help building a company. Its partners hold board roles; their backgrounds cover science, product development and commercial operations. Founders receive financing and advice. Investors in its private funds supply the capital. Patients and employers are generally customers of portfolio businesses. Keeping those relationships straight prevents the familiar mistake of describing a venture firm as if it sells every product it finances.

That is JAZZ’s place in the market: a specialist perspective crossing several conventional sectors. A healthcare investor might understand a clinical endpoint; a consumer investor might understand habit and retention. A company blending those disciplines benefits from asking both sets of questions before it spends the money.

“eventually biology is going to come after you”Zack Lynch, speaking at DTx East in 2019

Lynch’s warning at the conference concerned therapeutic mechanisms and evidence. A startup needs to explain what part of a disease process it intends to change. Otherwise, he argued, the eventual trial may fail to produce the evidence needed for reimbursement or a partnership. That is an unusually concrete instruction hiding inside an expansive investment thesis.

03 / A breakthrough still needs a checkout

The money deserves equal precision. A 2019 report put JAZZ’s human-performance venture fund at approximately $287 million. That was capital raised for investment. It should not be read as sales, a valuation of the management company or a statement of its assets today.

For the companies receiving venture money, another number matters: the price someone will actually pay. Akili’s 2022 annual report listed EndeavorRx at $450 for a 30-day prescription before discounts. Its plan addressed caregivers, clinicians and insurers. A person could want the treatment, a doctor could prescribe it, and an insurer could still decline to cover it. Three decisions stood between an idea and a dependable sale.

In September 2023, Akili announced a shift toward a non-prescription model and consumer subscriptions. Management pointed to early demand for EndeavorOTC and wanted less dependence on intermediaries. The restructuring included an approximately 40 percent workforce reduction. Here, the first commercial approach changed after the scientific milestone. Virtual Therapeutics completed its acquisition of Akili in July 2024.

Pear Therapeutics, another JAZZ portfolio company, filed Chapter 11 in April 2023. Its bankruptcy counsel later described an asset auction bringing just over $6 million. These events do not reveal JAZZ’s individual returns. They do show why an authorization or a public listing is an incomplete ending to an investment story.

04 / Copy the questions

The portfolio continues beyond therapeutic software. In July 2026, Transcripta Bio named JAZZ among existing investors while announcing $24 million raised since its Series A. The intended work included studies supporting regulatory submissions and preparation for clinical trials in neurological and neuromuscular diseases. Enveda, another portfolio company, announced a $311 million financing in September 2026 to advance medicines and its discovery platform.

For founders, the practical lesson is to prepare several answers. Define the person’s problem. Explain the mechanism. Show evidence appropriate to the claim. Name the buyer and map the steps between interest and payment. This is a reading of the portfolio, rather than a published JAZZ application checklist.

The approach becomes difficult when scientific development outlasts available capital, or when an improvement has no affordable route to the customer. Consumer enthusiasm cannot substitute for clinical evidence; evidence cannot force a purchase. An epilepsy implant and a sleep ring can share an investor. Each still has to earn its own way into somebody’s life.